Seminars in Hematology
Volume 40, Issue 3 , Pages 244-256 , July 2003

Systemic and primary cutaneous anaplastic large cell lymphomas

  • Marshall E. Kadin

      Affiliations

    • *Address correspondence to Marshall E. Kadin, MD, Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    • Departments of Pathology and Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    • ,
  • Christopher Carpenter

      Affiliations

    • Departments of Pathology and Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

References 

  1. Agnarsson B, Kadin ME. Ki-1-positive large-cell lymphoma: A morphologic and immunologic study of 19 cases. Am J Surg Pathol. 1988;12:264–274
  2. Agnarsson B, Vonderheid EC, Kadin ME. Cutaneous T-cell lymphoma with suppressor/cytotoxic phenotype: Identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol. 1990;22:569–577
  3. Amakawa R, Hakem A, Kundig TM, et al.  Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice. Cell. 1996;84:551–562
  4. Bai RY, Dieter P, Peschel C, et al.  Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998;18:6951–6961
  5. Bai RY, Ouyang T, Miething C, et al.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96:4319–4327
  6. Basarab T, Fraser-Edwards EA, Orchard G, et al.  Lymphomatoid papulosis in association with mycosis fungoides: A study of 15 cases. J Am Acad Dermatol. 1998;139:630–638
  7. Bekkenk MW, Geelen FAMJ, van Voorst VPC, et al.  Primary and secondary cutaneous CD30+ lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–13661
  8. Beljaards RC, Meijer CHLM, Scheffer E, et al.  Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol. 1989;135:1169–1178
  9. Benharroch D, Beguerian-Beydoyan Z, Lamant L, et al.  ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood. 1998;2076–2084
  10. Berti E, Tomasini D, Vermeer MH, et al.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483–492
  11. Bischof D, Pulford K, Mason DY, et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17:2312–2325
  12. Burg G, Kempf W, Kazakov D, et al.  Pyogenic lymphoma of the skin: A peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol. 2003;148:1–7
  13. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811–820
  14. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720–4728
  15. Chan J, Buchanan R, Fletcher C. Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol. 1990;14:983–988
  16. Chiarle R, Podda A, Prolla G, et al.  CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157–164
  17. Chiarle R, Podda A, Prolla G, et al.  CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163:194–205
  18. Chott A, Vonderheid EC, Olbricht S, et al.  The same dominant T cell clone is present in multiple regressing lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996;106:696–700
  19. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 1995;269:1875–1877
  20. Davis TH, Moron CC, Miller-Cassman R, et al.  Hodgkin’s disease, lymphomatoid papulosis, and cutaneous T cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992;326:1115–1122
  21. de Groot RP, Raaijmakers JA, Lammers JW, et al.  STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94:1108–1112
  22. DeCoteau J, Butmarc JR, Kinney MC, et al.  The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–3441
  23. Delsol G, Ralfkiaer E, Stein H, et al.  Anaplastic Large Cell Lymphoma. France: IARC, Lyon,; 2000;
  24. DeYoung AL, Duramad A, Winoto A. The TNF receptor family member CD30 is not essential for negative selection. J Immunol. 2000;165:6170–6173
  25. Duckett CS, Gedrich RW, Gilfillan MC, et al.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17:1535–1542
  26. Falini B, Pileri S, Stein H, et al.  Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki-1)-positive anaplastic large-cell lymphoma: Implications for the differential diagnosis between lymphoid and non-lymphoid malignancies. Hum Pathol. 1990;21:624–629
  27. Falini B, Pileri S, Zinzani P, et al.  ALK+ lymphoma: Clinico-pathologic findings and outcome. Blood. 1999;93:2697–2706
  28. Fischer P, Nacheva E, Mason DY, et al.  A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin’s lymphoma showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene. Blood. 1988;72:234–240
  29. Flynn K, Dehner K, Gajl-Peczalska K, et al.  Regressing atypical histiocytosis: A cutaneous proliferation of atypical neoplastic cells with unexpectely indolent clinical behavior. Cancer. 1982;49:959–970
  30. Fortson JS, Schroeter AL, Esterly NB. Cutaneous T-cell lymphoma (parapsoriasis en plaque). An association with pityriasis lichenoides et varioliformis acuta in young children. Arch Dermatol. 1990;126:1449–1453
  31. Fraga M, Brousset P, Schlaifer D, et al.  Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol. 1995;103:82–89
  32. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996;10:1724–1730
  33. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481–507
  34. Fujimoto J, Shiota M, Iwahara T, et al.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA. 1996;93:4181–4186
  35. Gascoyne R, Aoun P, Wu D, et al.  Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–3921
  36. Gedrich RW, Gilfillan MC, Duckett CS, et al.  CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996;271:12852–12858
  37. Gould JW, Eppes RB, Gilliam AC, et al.  Solitary primary cutaneous CD30+ large cell lymphoma of natural killer phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child. Am J Dermatopathol. 2000;22:422–428
  38. Gruss HJ, Boiani N, Williams DE, et al.  Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045–2056
  39. Gu H, Pratt JC, Burakoff SJ, et al.  Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell. 1998;2:729–740
  40. Harlin H, Podack E, Boothby M, et al.  TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol. 2002;169:2451–2459
  41. Harris N, Jaffe E, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;1361–1392
  42. Hernandez L, Pinyol M, Hernandez S, et al.  TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 1999;94:3265–3268
  43. Horie R, Watanabe T. CD30: Expression and function in health and disease. Semin Immunol. 1998;10:457–470
  44. Horie R, Watanabe T, Morishita Y, et al.  Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 2002;21:2493–2503
  45. Hubinger G, Muller E, Scheffrahn I, et al.  CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene. 2001;20:590–598
  46. Hubinger G, Scheffrahn I, Muller E, et al.  The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. Exp Hematol. 1999;27:1796–1805
  47. Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704–131710
  48. Inghirami G, Macri L, Cesarman E, et al.  Molecular characterization of CD30+ anaplastic large cell lymphomas: High frequency of c-myc proto-oncogene activation. Blood. 1994;3581–3590
  49. Jhala D, Medeiros LJ, Lopez-Terrada D, et al.  Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients. Am J Clin Pathol. 2000;114:478–482
  50. Jundt F, Anagnostopoulos I, Forster R, et al.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398–3403
  51. Jung W, Krueger S, Renner C, et al.  Opposite effects of the CD30 ligand are not due to CD30 mutations: Results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol. 1994;31:1329–1334
  52. Kadin M. Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann Oncol. 1994;5:S25–S30
  53. Kadin M, Drews R, Samel A, et al.  Hodgkin’s lymphoma of T-cell type: Clonal association with a CD30+ cutaneous lymphoma. Hum Pathol. 2001;32:1269–1272
  54. Kadin M, Sako E, Berliner N, et al.  Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood. 1986;68:1042–1049
  55. Kadin ME. The spectrum of Ki-1+ cutaneous lymphomas. In Current Problems in Dermatology. In:  eds van Vloten WA,  Willemze R,  Lange-Vejlsgaard G editor. Farmington, CT: Karger,; 1990;p. 132–143
  56. Kadin ME, Nasu K, Sako D, et al.  Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin’s disease associated antigens. Am J Pathol. 1985;119:315–325
  57. Kanzler H, Kueppers R, Hansmann M-L, et al.  Hodgkin and H/RS cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:495–505
  58. Kaudewitz P, Stein H, Plewig G, et al.  Hodgkin’s disease followed by lymphomatoid papulosis: Immunophenotypic evidence for a close relationship between Hodgkin’s disease and lymphomatoid papulosis. J Am Acad Dermatol. 1990;22:999–1006
  59. Kinney MC, Collins RD, Greer J, et al.  A small cell predominant variant of Ki-1 (CD30+) T-cell lymphoma. Am J Surg Pathol. 1993;17:859–868
  60. Krenacs L, Wellmann A, Sorbara L, et al.  Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null cell type and Hodgkin’s disease: Evidence for a distinct cellular origin. Blood. 1997;89:980–989
  61. Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30-positive anaplastic large cell lymphoma. Report of 27 cases. J Cutan Pathol. 1993;20:193–202
  62. Kuefer M, Look A, Pulford K, et al.  Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 1997;2901–2910
  63. Kummer JA, Vermeer MH, Dukers D, et al.  Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol. 1990;109:636–640
  64. Lacronique V, Boureux A, Monni R, et al.  Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076–2083
  65. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002;118:773–779
  66. Lamant L, Dastugue N, Pulford K, et al.  A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999;93:3088–3095
  67. Le Beau M, Bitter M, Larson R. The t(2;5)(p23;q35); a recurring abnormality in Ki-1-positive anaplastic large-cell lymphoma. Leukemia. 1989;3:866–1890
  68. Lederman NS, Sober AJ, Harrist TJ, et al.  Lymphomatoid papulosis following Hodgkin’s disease. J Am Acad Dermatol. 1987;16:331–335
  69. Levi E, Wang Z, Petrogiannis-Haliotis T, et al.  Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol. 2000;115:1034–1040
  70. Levy DE, Darnell JE. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–662
  71. Li S, Ross D, Kadin M, et al.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol. 2001;158:1231–1237
  72. Mann KP, Hall B, Kamino H, et al.  Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol. 1995;19:407–416
  73. Mao X, Orchard G, Lillington DM, et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003;101:1513–1519
  74. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307–4312
  75. Morris SW, Kirstein M, Valentine M, et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkins lymphoma. Science. 1994;263:1281–1284
  76. Mueschen M, Rajewsky K, Brauninger A, et al.  Rare occurence of classical Hodgkin’s disease as a T cell lymphoma. J Exp Med. 2000;191:387–394
  77. Muta H, Boise LH, Fang L, et al.  CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol. 2000;165:5105–5111
  78. Nasu K, Said J, Vonderheid E, et al.  Immunopathology of cutaneous T-cell lymphomas. Am J Pathol. 1985;119:436–447
  79. Nieborowska-Skorska M, Slupianek A, Xue L, et al.  Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001;61:6517–6523
  80. Nishikori M, Maesako Y, Ueda C, et al.  High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin’s disease. Blood. 2003;101:2789–2796
  81. Pasqualucci L, Wasik M, Teicher BA, et al.  Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995;85:2139–2146
  82. Paulli M, Berti E, Rosso R, et al.  CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1996;13:1343–1354
  83. Pileri S, Bocchia M, Baroni C, et al.  Anaplastic large cell lymphoma (CD30+/KI-1+): Results of a prospective clinicopathologic study of 69 cases. Br J Haematol. 1994;86:513–523
  84. Powell IF, Li T, Jack HM, et al.  Construction and expression of a soluble form of human CD30 ligand with functional activity. J Leukoc Biol. 1998;63:752–757
  85. Pulford K, Lamant L, Morris SW, et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394–1404
  86. Raetz E, Perkins S, Carlson M, et al.  The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol. 2002;161:875–883
  87. Rubin B, Lawrence B, Perez-Atayde A, et al.  TMP-ALK fusion genes and ALK expression in inflammatory myofibroblastic tumor (IMT). Mod Pathol. 2000;13:15A; (abstr)
  88. Rudiger T, Jaffe E, Delsol G, et al.  Workshop report on Hodgkin’s lymphoma and related diseases (Grey zone lymphoma). Ann Oncol. 1998;9:531–1538
  89. Saffer H, Wahed A, Rassidakis G, et al.  Clusterin expression in malignant lymphomas: A Survey of 266 cases. Mod Pathol. 2002;15:1221–1226
  90. Schwab U, Stein H, Gerdes J, et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299:65–67
  91. Seitz V, Hummel M, Marafioti T, et al.  Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin’s disease. Blood. 2000;95:3020–3024
  92. Shiota M, Mori S. The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Leuk Lymphoma. 1996;23:25–32
  93. Shuai K, Halpern J, ten Hoeve J, et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247–254
  94. Slupianek A, Nieborowska-Skorska M, Hoser G, et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61:2194–2199
  95. Smith CA, Gruss HJ, Davis T, et al.  CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349–1360
  96. Songyang Z, Shoelson SE, Chaudhuri M, et al.  SH2 domains recognize specific phosphopeptide sequences. Cell. 1993;72:767–778
  97. Stein H, Mason DY, Gerdes J, et al.  The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissues: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–858
  98. Steinhoff M, Hummel M, Anagnostopoulos I, et al.  Single cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common T-cell origin. Blood. 2001;100:578–584
  99. Suzuki R, Kagami Y, Takeuchi K, et al.  Prognostic significance of CD56 expression for ALK-positive and -negative anaplastic large cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993–3000
  100. Tian ZG, Longo DL, Funakoshi S, et al.  In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 1995;55:5335–5341
  101. Touriol C, Greenland C, Lamant L, et al.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: Two cases expressing ALK kinase fused to CLTCL (clatherin chain polypeptide-like). Blood. 2000;95:3204–3207
  102. Trinei M, Lanfrancone L, Campo E, et al.  A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000;60:793–798
  103. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501
  104. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative diseases. J Am Acad Dermatol. 1996;34:470–481
  105. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer. 1992;70:2951–2957
  106. Wellmann A, Thieblemaon C, Pittaluga S, et al.  Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398–404
  107. Wilbanks AM, Mahajan S, Frank DA, et al.  TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000;28:584–593
  108. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973–980
  109. Willemze R, Kerl H, Sterry W, et al.  EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
  110. Willemze R, Meijer CJLM, van Vloten WA, et al.  The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982;107:131–144
  111. Willenbrock K, Ichinohasama R, Kadin M, et al.  T-cell variant of classical Hodgkin’s lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction. Lab Invest. 2002;82:1103–1109
  112. Wlodarska I, de wolfe-Peeters C, Falini B, et al.  The cryptic inv(2)(o23;q35) defines a new molecular subtype of ALK-positive anaplastic large-cell lymphoma. Blood. 1998;92:2688–12695
  113. Zamo A, Chiarle R, Piva R, et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21:1038–1047
  114. Zhang Q, Raghunath RN, Xue L, et al.  Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168:466–474
  115. Zinzani P, Bendandi M, Martelli M, et al.  Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol. 1996;14:955–962
  116. Chiarle R, Gong JZ, Guasparri J, et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101:1919–1927

☆ Supported in part by NIHM Grant No. CA 92232 (C.C.) and P50-CA93683 (M.E.K.).

PII: S0037-1963(03)00138-0

Seminars in Hematology
Volume 40, Issue 3 , Pages 244-256 , July 2003

Article Tools

* Image Usage & Resolution